LJPC 1010

Drug Profile

LJPC 1010

Alternative Names: LJPC-1010

Latest Information Update: 11 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Polysaccharides
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 08 May 2015 LJPC 1010 is available for licensing as of 08 May 2015. www.ljpc.com
  • 08 May 2015 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (PO)
  • 08 May 2015 La Jolla Pharmaceutical Company terminates a phase I trial in Non-alcoholic steatohepatitis prior to enrolment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top